---
title: "Exelixis (NASDAQ:EXEL) Stock Price Down 5.6%  - Here's Why"
description: "Exelixis, Inc. (NASDAQ:EXEL) saw its stock price decline by 5.6% to $34.38 during trading, with a significant drop in volume. Analysts have mixed ratings, with price targets ranging from $23 to $41. T"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/226249781.md"
published_at: "2025-01-25T21:22:05.000Z"
---

# Exelixis (NASDAQ:EXEL) Stock Price Down 5.6%  - Here's Why

> Exelixis, Inc. (NASDAQ:EXEL) saw its stock price decline by 5.6% to $34.38 during trading, with a significant drop in volume. Analysts have mixed ratings, with price targets ranging from $23 to $41. The company reported a quarterly EPS of $0.40, exceeding estimates, and a revenue of $539.5 million, up 14.3% year-over-year. Insider trading activity included sales by executives, and institutional investors have recently adjusted their holdings. Exelixis has an average rating of "Moderate Buy" with a price target of $35.00.

Exelixis, Inc. (NASDAQ:EXEL - Get Free Report) was down 5.6% during trading on Wednesday . The company traded as low as $34.39 and last traded at $34.38. Approximately 399,288 shares changed hands during trading, a decline of 83% from the average daily volume of 2,414,278 shares. The stock had previously closed at $36.43.

## Analyst Ratings Changes

-   3 Stocks to Buy for a Soft Landing, If There Is One

Several research firms recently issued reports on EXEL. Stephens lifted their price target on shares of Exelixis from $23.00 to $29.00 and gave the stock an "equal weight" rating in a research note on Wednesday, October 30th. The Goldman Sachs Group upgraded Exelixis to a "strong sell" rating in a research note on Tuesday, October 15th. Wells Fargo & Company raised their price objective on Exelixis from $32.00 to $36.00 and gave the company an "overweight" rating in a research note on Wednesday, October 30th. Morgan Stanley upped their target price on Exelixis from $26.00 to $28.00 and gave the company an "equal weight" rating in a research report on Friday, October 11th. Finally, Oppenheimer cut Exelixis from an "outperform" rating to a "market perform" rating and reduced their target price for the company from $41.00 to $33.00 in a research note on Friday. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Exelixis presently has an average rating of "Moderate Buy" and an average price target of $35.00.

**View Our Latest Analysis on EXEL**

## Exelixis Stock Down 5.1 %

-   3 Strong Biotech Performers To Watch As Sector Nears Breakout

The firm's 50 day simple moving average is $34.91 and its 200 day simple moving average is $29.64. The company has a market cap of $9.25 billion, a price-to-earnings ratio of 20.76, a price-to-earnings-growth ratio of 0.72 and a beta of 0.53.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The firm had revenue of $539.50 million for the quarter, compared to analysts' expectations of $490.31 million. During the same period last year, the firm earned $0.10 EPS. The firm's revenue was up 14.3% compared to the same quarter last year. Analysts anticipate that Exelixis, Inc. will post 1.74 EPS for the current fiscal year.

## Insider Activity at Exelixis

-   7 Best Cancer Stocks to Invest in Now

In other Exelixis news, EVP Dana Aftab sold 1,162 shares of the business's stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $31.40, for a total value of $36,486.80. Following the sale, the executive vice president now directly owns 498,945 shares in the company, valued at approximately $15,666,873. The trade was a 0.23 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jeffrey Hessekiel sold 60,000 shares of Exelixis stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $36.67, for a total transaction of $2,200,200.00. Following the completion of the transaction, the executive vice president now directly owns 486,059 shares in the company, valued at $17,823,783.53. This represents a 10.99 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 314,736 shares of company stock worth $10,849,110 over the last quarter. 2.85% of the stock is currently owned by company insiders.

## Institutional Investors Weigh In On Exelixis

Institutional investors and hedge funds have recently modified their holdings of the stock. USA Financial Formulas acquired a new position in shares of Exelixis in the 4th quarter valued at $32,000. V Square Quantitative Management LLC purchased a new position in shares of Exelixis in the third quarter worth approximately $30,000. UMB Bank n.a. boosted its stake in Exelixis by 68.4% in the 4th quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company's stock worth $45,000 after purchasing an additional 553 shares during the period. Brooklyn Investment Group purchased a new stake in shares of Exelixis in the third quarter valued at $42,000. Finally, MassMutual Private Wealth & Trust FSB raised its position in Exelixis by 18.1% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company's stock valued at $63,000 after buying an additional 290 shares during the period. 85.27% of the stock is owned by institutional investors and hedge funds.

## About Exelixis

(Get Free Report)

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

## Featured Stories

-   Five stocks we like better than Exelixis
-   How Investors Can Find the Best Cheap Dividend Stocks
-   Why Energy Transfer Stock Could Soar to New Highs in 2025
-   How to Buy Cheap Stocks Step by Step
-   3 Buy-and-Hold Stocks for Long-Term Growth
-   Basic Materials Stocks Investing
-   Despite Short-Term Risks Freeport McMoran Worth a Look

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

## Should You Invest $1,000 in Exelixis Right Now?

Before you consider Exelixis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exelixis wasn't on the list.

While Exelixis currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [EXEL.US - Exelixis](https://longbridge.com/en/quote/EXEL.US.md)
- [NDAQ.US - Nasdaq](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 伊克力西斯董事 Oliver Bob 出售了股份 | Oliver Bob，Exelixis 的董事，於 2026 年 2 月 13 日出售了 30,250 股普通股，交易金額為 1,325,339 美元。此次銷售包括 9,088 股，每股價格為 43.61 美元，以及 21,162 股，按加 | [Link](https://longbridge.com/en/news/276292701.md) |
| EXEL 工業公司報告稱，截至 2026 年 1 月，公司擁有 679 萬股和 989 萬投票權 | EXEL Industries SA 報告稱，截至 2026 年 1 月 31 日，其股本中擁有 6,787,900 股股份。該公司擁有 9,890,341 個理論投票權，扣除無投票權股份後，實際可行使的投票權為 9,884,832 個。該 | [Link](https://longbridge.com/en/news/275592323.md) |
| 黃仁勳稱將發佈「令世界驚訝」新晶片「所有技術都已經逼近極限」 | 英偉達執行長黃仁勳在接受《韓國經濟日報》採訪時透露，將於 2026 年 3 月 16 日在聖何塞的 GTC 大會上發布一款「令世界驚訝」的新晶片。他表示，所有技術都已逼近極限，但有信心通過團隊合作克服挑戰。新晶片可能基於 Rubin 架構或 | [Link](https://longbridge.com/en/news/276297645.md) |
| 三隻先鋒基金 ETF 搭乘 AI 熱潮，與 NVIDIA、Microsoft 和科技巨頭同行 | 人工智能正在改變科技行業，推動對半導體、雲計算和軟件的投資。對於長期投資者而言，Vanguard ETFs 提供了對領先人工智能公司的多元化投資機會。三個值得關注的基金是 Vanguard 信息科技 ETF (VGT)、Vanguard 標 | [Link](https://longbridge.com/en/news/276051127.md) |
| OpenAI 億萬富翁 CEO Sam Altman 的職業發展歷程 | OpenAI 億萬富翁首席執行官山姆·阿爾特曼的職業崛起 | [Link](https://longbridge.com/en/news/276051606.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
